Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors as its primary route of elimination is non-renal (biliary/GI excretion).
## Primary Indications
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
* **Safety and Efficacy:** Not established in pediatric patients under 18 years of age.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment required.
* **Hepatic Impairment:** No dosage adjustment required.
* **Geriatric:** No dosage adjustment required based on age.
## Contraindications
* History of a serious hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
## Adverse Effects
* **Common:** Nasopharyngitis.
* **Serious:** Pancreatitis (discontinue if suspected), severe and disabling arthralgia, bullous pemphigoid, and hypersensitivity reactions.
* **Hypoglycemia:** Risk is low when used as monotherapy; increased risk when used in combination with insulin or insulin secretagogues (e.g., sulfonylureas).
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin plasma concentrations. If co-administration is necessary, monitor glycemic control closely.
## Monitoring
* **Efficacy:** HbA1c (typically every 3–6 months) and fingerstick blood glucose monitoring.
* **Safety:** Monitor for signs/symptoms of pancreatitis (persistent, severe abdominal pain) and bullous pemphigoid (blistering or erosions).
## Clinical Pearls
* **No Renal Adjustment:** Unlike other DPP-4 inhibitors (sitagliptin, saxagliptin), linagliptin does not require renal dose adjustments, making it a preferred choice in patients with chronic kidney disease.
* **Administration:** Can be taken with or without food.
* **Pancreatitis Risk:** Advise patients to stop the medication and seek immediate medical attention if severe abdominal pain occurs.
* **Weight Neutral:** Linagliptin is generally weight-neutral.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Prescribing practices, local clinical protocols, and pharmacy guidelines may vary. Always verify current prescribing information, package inserts, and clinical guidelines before administering or prescribing any medication.
